Tumor necrosis factor (TNF-α) is a key regulator of the inflammatory and tissue destruc-tive pathways in rheumatoid arthritis (RA). The clinical success of anti-TNF-α and an-ti-IL-17 biologics has validated the concept that cytokine blockade is beneficial in RA. However, as these drugs are parenterally administered, our efforts are directed at identifying a novel orally active TNF-α inhibitor with a therapeutic profile similar to that of biologics. Since plants are natural immunomodulators, we explored the immunomodulatory potential of Sphaeranthus indicus extract. In our studies, the extract dose-dependently inhibited the release of cytokines in stimulated human peripheral blood mononuclear cells (hPBMCs), and their spontaneous release in synovial cells derived from patients suffering from RA. TNF-α and IFN-γ induced release of p40 subunit of IL-12/ IL-23, and p19 subunit of IL-23 in differentiated THP-1 cells is potently blocked. The expression of endothelial cell adhesion molecules in TNF-α-stimulated HUVECs was also potently inhibited. The oral treatment significantly and dose-dependently reduced LPS-induced TNF-α and IL-1β production in mice. Disease regression was seen in collagen-induced arthritis in DBA/1J mice, which was validated along with radiological and histopathological evaluation. Therefore, the extract of Sphaeranthus indicus could be used in the management of inflammatory conditions.
References
[1]
Feldmann, M. (2008) Many Cytokines Are Very Useful Therapeutic Targets in Disease. The Journal of Clinical Investigation, 118, 3533-3536. http://dx.doi.org/10.1172/JCI37346
[2]
Taylor, P.C. (2001) Anti-TNF Therapy for Rheumatoid Arthritis and Other Inflammatory Diseases. Molecular Biotechnology, 19, 153-168. http://dx.doi.org/10.1385/mb:19:2:153
[3]
Weinblatt, M.E., Keystone, E.C., Furst, D.E., Moreland, L.W., Weisman, M.H., Birbara, C.A. and Teoh, L.A. (2003) Adalimumab, a Fully Human Anti-Tumor Necrosis Factor α Monoclonal Antibody, for the Treatment of Rheumatoid Arthritis in Patients Taking Concomitant Methotrexate: The ARMADA Trial. Arthritis & Rheumatism, 48, 35-45. http://dx.doi.org/10.1002/art.10697
[4]
Uyemura, K., Yamamura, M., Fivenson, D.F., Modlin, R.L. and Nickoloff, B.J. (1993) The Cytokine Network in Lesional and Lesion-Free Psoriatic Skin Is Characterized by a T-Helper Type 1 Cell-Mediated Response. Journal of Investigative Dermatology, 101, 701-705. http://dx.doi.org/10.1111/1523-1747.ep12371679
[5]
Ettehadi, P., Greaves, M., Wallach, D., Aderka, D. and Camp, R. (1994) Elevated Tumour Necrosis Factor-Alpha (TNF-α) Biological Activity in Psoriatic Skin Lesions. Clinical & Experimental Immunology, 96, 146-151. http://dx.doi.org/10.1111/j.1365-2249.1994.tb06244.x
[6]
Mease, P.J., Goffe, B.S., Metz, J., Vander Stoep, A., Finck, B. and Burge, D.J. (2000) Etanercept in the Treatment of Psoriatic Arthritis and Psoriasis: A Randomised Trial. The Lancet, 356, 385-390. http://dx.doi.org/10.1016/S0140-6736(00)02530-7
[7]
Reich, K., Nestle, F.O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L.T. and Griffiths, C.E. (2005) Infliximab Induction and Maintenance Therapy for Moderate-to-Severe Psoriasis: A Phase III, Multicentre, Double-Blind Trial. The Lancet, 366, 1367-1374. http://dx.doi.org/10.1016/S0140-6736(05)67566-6
[8]
Leonardi, C., Matheson, R., Zachariae, C., Cameron, G., Li, L., Edson-Heredia, E., Braun, D. and Banerjee, S. (2012) Anti-Interleukin-17 Monoclonal Antibody Ixekizumab in Chronic Plaque Psoriasis. New England Journal of Medicine, 366, 1190-1199. http://dx.doi.org/10.1056/NEJMoa1109997
[9]
Yeilding, N., Szapary, P., Brodmerkel, C., Benson, J., Plotnick, M., Zhou, H., Goyal, K., et al. (2011) Development of the IL-12/23 Antagonist Ustekinumab in Psoriasis: Past, Present, and Future Perspectives. Annals of the New York Academy of Sciences, 1222, 30-39. http://dx.doi.org/10.1111/j.1749-6632.2011.05963.x
[10]
Rohit, R., Mahendra, S., Richa, S., Kavitha, M. and Vikram, S.S. (2014) A Clinical Study on the effect of Punarnavadi churna, Singhanada guggulu in the management of Amavata (Rheumatoid Arthritis). International Journal of Ayurveda and Pharma Research, 2, 46-54.
[11]
Ramachandran, S. (2013) Review on S. indicus Linn. (Kottaikkarantai). Pharmacognosy Reviews, 7, 157-169. http://dx.doi.org/10.4103/0973-7847.120517
[12]
Chakrabarti, D., Suthar, A.S., Jayaraman, G., Muthuvelan, B., Sharma, S. and Padigaru, M. (2012) NPS31807, a Standardized Extract from Sphaeranthus indicus, Inhibits Inflammatory, Migratory and Proliferative Activity in Keratinocytes and Immune Cells. Pharmacology & Pharmacy, 3, 178-194. http://dx.doi.org/10.4236/pp.2012.32025
[13]
Jansky, L., Reymanova, P. and Kopecky, J. (2003) Dynamics of Cytokine Production in Human Peripheral Blood Mononuclear Cells Stimulated by LPS, or Infected by Borrelia. Physiological Research, 52, 593-598.
[14]
Brennan, F.M., Chantry, D., Jackson, A., Maini, R. and Feldmann, M. (1989) Inhibitory Effect of TNF Alpha Antibodies on Synovial Cell Interleukin-1 Production in Rheumatoid Arthritis. Lancet, 334, 244-247. http://dx.doi.org/10.1016/S0140-6736(89)90430-3
[15]
Kamata, M., Tada, Y., Tatsuta, A., Kawashima, T., Shibata, S., Mitsui, H., Asano, Y., Sugaya, M., Kadono, T., Kanda, N., Watanabe, S. and Sato, S. (2013) Ciclosporin A Inhibits Production of Interleukin-12/23p40 and Interleukin-23 by the Human Monocyte Cell Line, THP-1. Clinical and Experimental Dermatology, 38, 545-548. http://dx.doi.org/10.1111/ced.12110
[16]
Balachandran, S., Gadekar, P.K., Parkale, S., Yadav, V.N., Kamath, D., Ramaswamy, S., Sharma, S., Vishwakarma, R.A. and Dagia, N.M. (2011) Synthesis and Biological Activity of Novel MIF Antagonists. Bioorganic & Medicinal Chemistry Letters, 21, 1508-1511. http://dx.doi.org/10.1016/j.bmcl.2010.12.127
[17]
Béchard, D., Scherpereel, A., Hammad, H., Gentina, T., Tsicopoulos, A., Aumercier, M., Pestel, J., et al. (2001) Human Endothelial-Cell Specific Molecule-1 Binds Directly to the Integrin CD11a/CD18 (LFA-1) and Blocks Binding to Intercellular Adhesion Molecule-1. The Journal of Immunology, 167, 3099-3106. http://dx.doi.org/10.4049/jimmunol.167.6.3099
[18]
Kim, K., Choi, Y., Lee, N., Park, K., Kim, G., Park, J., Kim, B., Lim, Y., et al. (2011) 5-Hydroxymethylfurfural from Black Garlic Extract Prevents TNFα-Induced Monocytic Cell Adhesion to HUVECs by Suppression of Vascular Cell Adhesion Molecule-1 Expression, Reactive Oxygen Species Generation and NF-κB Activation. Phytotherapy Research, 25, 965-974. http://dx.doi.org/10.1002/ptr.3351
[19]
Moreira, L., Wang, J., Sarno, N. and Kaplan, G. (1997) Thalidomide Protects Mice against LPS-Induced Shock. Brazilian Journal of Medical and Biological Research, 10, 1199-1207. http://dx.doi.org/10.1590/s0100-879x1997001000010
[20]
Terato, K., Karen, H., Michael, C., John, S., Alexander, T. and Andrew, K. (1985) Collagen-Induced Arthritis in Mice. Localization of an Arthritogenic Determinant to a Fragment of the Type II Collagen Molecule. The Journal of Experimental Medicine, 162, 637-646. http://dx.doi.org/10.1084/jem.162.2.637
[21]
Papp, A., Langley, G., Lebwohl, M., Krueger, G., Szapary, P. and Yeilding, N. (2008) Efficacy and Safety of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients with Psoriasis: 52-Week Results from a Randomised, Double-Blind, Placebo-Controlled Trial (PHOENIX 2). Lancet, 371, 1675-1684. http://dx.doi.org/10.1016/S0140-6736(08)60726-6
[22]
Ding, C., Xu, J. and Li, J. (2008) ABT-874, a Fully Human Monoclonal Anti-IL-12/IL-23 Antibody for the Potential Treatment of Autoimmune Diseases. Current Opinion in Investigational Drugs, 9, 515-522.
[23]
Fukuda, T., Sumichika, H., Murata, M., Hanano, T., Adachi, K. and Hisadome, M. (2000) A Novel Dual Regulator of Tumour Necrosis Factor-α and Interleukin-10 Protects Mice from Endotoxin-Induced Shock. European Journal of Pharmacology, 391, 317-320. http://dx.doi.org/10.1016/S0014-2999(00)00096-0
[24]
Wooley, H., Luthra, S., Krco, J., Stuart, M. and David, S. (1984) Type II Collagen—Induced Arthritis in Mice. Arthritis & Rheumatism, 27, 1010-1017. http://dx.doi.org/10.1002/art.1780270907
[25]
Simmonds, R.E. and Foxwell, B.M. (2008) Signalling, Inflammation and Arthritis: NF-κB and Its Relevance to Arthritis and Inflammation. Rheumatology, 5, 584-590. http://dx.doi.org/10.1093/rheumatology/kem298
[26]
Klimiuk, P., Sierakowski, S., Latosiewicz, R., Cylwik, J., Cylwik, B., Skowronski, J. and Chwiecko, J. (2002) Soluble Adhesion Molecules (ICAM-1, VCAM-1, and E-Selectin) and Vascular Endothelial Growth Factor (VEGF) in Patients with Distinct Variants of Rheumatoid Synovitis. Annals of the Rheumatic Diseases, 9, 804-809. http://dx.doi.org/10.1136/ard.61.9.804
[27]
Van den Berg, B. and Miossec, P. (2009) IL-17 as a Future Therapeutic Target for Rheumatoid Arthritis. Nature Reviews Rheumatology, 10, 549-553. http://dx.doi.org/10.1038/nrrheum.2009.179